Ghent University Academic Bibliography

Journal Article
A1
open access

Autogene cevumeran with or without atezolizumab in advanced solid tumors : a phase 1 trial

Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L. Siu, Patricia LoRusso, Claire F. Friedman, Ani S. Balmanoukian, Michael Gordon, Jeffrey Yachnin, Sylvie Rottey (UGent) , et al.

(2025) NATURE MEDICINE. 31(1). p.152-164

Add to list

Journal Article
A1
open access

Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors

Areeba Patel, Kirsten Göbel, Sebastian Ille, Felix Hinz, Natalie Schoebe, Henri Bogumil, Jochen Meyer, Michelle Brehm, Helin Kardo, Daniel Schrimpf, et al.

(2025) NATURE MEDICINE. 31. p.1567-1577

Add to list

Miscellaneous

Structured programs to train the next generation of clinician scientists

Anette Melk, Carl Grabitz, Johanna Ernst, Thorsten Saenger, Eva Degraeuwe (UGent) , Beatrice Beck Schimmer, Johan Vande Walle (UGent) , Karolis Ažukaitis, Berent Prakken, Elias Campo, et al.

(2025) NATURE MEDICINE. 31(1). p.24-27

Add to list

Journal Article
A1
open access

Data governance must consider the interests of the global community

Jon Rueda, Sebastian Porsdam Mann, Janet Delgado, Brian D. Earp, Karin Jongsma, Heidi Mertes (UGent) , Davide Battisti, Íñigo de Miguel Beriain, Gabriela Lenarczyk, Vera Lúcia Raposo, et al.

(2025) NATURE MEDICINE. 31(10). p.3223-3224

Add to list

Women’s health and rights in the twenty-first century

Samuel Akombeng Ojong, Marleen Temmerman (UGent) , Rajat Khosla and Flavia Bustreo

(2024) NATURE MEDICINE. 30(6). p.1547-1555

Add to list

Journal Article
A1
open access

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer : a phase 2 adaptive trial

Iris Nederlof, Olga I. Isaeva, Manon de Graaf, Robbert C. A. M. Gielen, Noor A. M. Bakker, Adrianne L. Rolfes, Hannah Garner, Bram Boeckx, Joleen J. H. Traets, Ingrid A. M. Mandjes, et al.

(2024) NATURE MEDICINE. 30(11). p.3223-3235

Add to list

Journal Article
A1
open access

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Sohyon Lee, Tobias Weiss, Marcel Bühler (UGent) , Julien Mena, Zuzanna Lottenbach, Rebekka Wegmann, Miaomiao Sun, Michel Bihl, Bartłomiej Augustynek, Sven P. Baumann, et al.

(2024) NATURE MEDICINE. 30(11). p.3196-3208

Add to list

Journal Article
A1
open access

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial

Bram De Laere (UGent) , Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D'hondt (UGent) , Rebecka Bergstrom, Venkatesh Chellappa, Markus Mayrhofer, et al.

(2024) NATURE MEDICINE. 30(11). p.3291-3302

Add to list

Miscellaneous
open access

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial (vol 30, pg 3291, 2024)

Bram De Laere (UGent) , Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D'hondt (UGent) , Rebecka Bergstrom, Venkatesh Chellappa, Markus Mayrhofer, et al.

(2024) NATURE MEDICINE. 30(11). p.3381-3381

Add to list

Journal Article
A1
open access

RANKL blockade for erosive hand osteoarthritis : a randomized placebo-controlled phase 2a trial

Ruth Wittoek (UGent) , Gust Verbruggen, Tine Vanhaverbeke (UGent) , Roos Colman (UGent) and Dirk Elewaut (UGent)

(2024) NATURE MEDICINE. 30(3). p.829-836

Academic Bibliography

Autogene cevumeran with or without atezolizumab in advanced solid tumors : a phase 1 trial

Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors

Structured programs to train the next generation of clinician scientists

Data governance must consider the interests of the global community

Women’s health and rights in the twenty-first century

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer : a phase 2 adaptive trial

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer : an outcome-adaptive randomized platform trial (vol 30, pg 3291, 2024)

RANKL blockade for erosive hand osteoarthritis : a randomized placebo-controlled phase 2a trial

Contents

Support

Contact